Vaccines are Safe for Kids with Kidney Disease 13 links

• ANSARA PIEBENGA
• VACCINES ARE SAFE FOR KIDS WITH KIDNEY DISEASE!
• Transplant v1
• Transplant v2
• Transplant v3

Building Blocks of Infection Prevention and Control 1 link

• Filtering Through IPC Information in Outpatient Dialysis Facilities

Infection Control in the Dialysis Settings 5 links

• Decreasing the Risk of Dialysis-Related Infections
• Hand Hygiene for Infection Prevention
• Personal Protective Equipment (PPE) for Infection Prevention
• Injection Safety for Infection Prevention
• Environmental Cleaning and Disinfection for Infection Prevention

• Additional ASN Resources
• Materials for Mentors
• Materials for Mentees

Elevator Pitch Resources 5 links

• 5 Elevator Pitch Examples (Plus How to Write and Deliver Yours)
• Perfect Elevator Pitch - Best Examples and Templates
• Best Elevator Pitch Examples, Templates, and Tactics
• How to Give an Effective Elevator Pitch
• Crafting a Compelling Elevator Pitch

Microaggressions 3 links

• What Are Microaggressions?
• Say What? Microaggressions, Your Health and What To Do About Them
• Professionalism: microaggression in the healthcare setting

Giving Feedback 1 link

• Three Goals of Giving Feedback

Identity and Intersectionality 3 links

• Generation X: Implications for faculty recruitment and development in academic health centers
• The work that remains at the intersection of gender and career development
• Why men still get more promotions than women

Leadership 2 links

• Crisis Leadership
• What Makes a Leader? Harvard Business Review 2024

Resources for Mentees 2 links

• Additional ASN Resources for Mentees
• OMA Knowledge Center

Early Mentoring 2 links

• Early Mentoring Conversations — Preparing The Relationship
• Mentoring Checklist

Mentoring Across Differences 5 links

• Mentoring Across Differences
• Thomas DA. The truth about mentoring minorities. Race matters. Harv Bus Rev. 2001 Apr;79(4):98-107, 168. PMID: 11299697.
• Lewellen-Williams, C. et al. The POD: A new model for mentoring underrepresented minority faculty. Acad Med 2006; 81-275-279.
• Bickel J. When "You're not the boss of me": Mentoring Across generational differences. In Mentoring: Program Development, Keel M. (ed), Nova Science Publishers Inc., 2009: 143-152.
• Maxwell, John. Mentoring 101: What Every Leader Needs to Know. Nashville: Thomas Nelson, 2008.

Sample Mentor/Mentee Agreements 3 links

• Mentor-Mentee Agreement (pdf)
• Mentor-Mentee Agreement (docx)
• Mentor-Mentee Agreement Sample University of Washington

Intravenous Amino Acids for Kidney Protection 2 links

• View Webinar
• Read Article

SOX9 switch activity determines healing with or without fibrosis after AKI 2 links

• View Webinar
• Read Article

Teprasiran for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery 2 links

• View Webinar
• Read Article

Automated medication-targeted alerts on AKI outcomes 3 links

• View Webinar
• Read Article
• Unanswered Questions from Webinar

Maladaptive proximal tubule cell dedifferentiation and renal fibrosis 2 links

• View Webinar
• Read Article

American Journal of Health-System Pharmacy 1 link

• Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions

American Journal of Kidney Diseases (AJKD) 3 links

• Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021
• Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
• Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate

Annals of Internal Medicine 1 link

• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Circulation 2 links

• Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
• Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association

Clinical Biochemistry 1 link

• An investigation of enzymatic creatinine interference in a patient receiving dopamine and dobutamine

Clinical Chemistry 3 links

• An Update on Reported Adoption of 2021 CKD-EPI Estimated Glomerular Filtration Rate Equations | Clinical Chemistry
• National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories
• Reporting Estimated Glomerular Filtration Rate (eGFR) for Adults | Chemistry Resource Committee

Clinical Journal of the American Society of Nephrology (CJASN) 1 link

• Precision in GFR Reporting Let’s Stop Playing the Race Card

Journal of the American Medical Association (JAMA) 1 link

• Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure

Journal of the American Society of Nephrology (JASN) 3 links

• Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report from the NKF-ASN Task Force
• A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
• What Does the American Heart Association Framework Mean for Nephrology?

Kidney360 1 link

• Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR

Kidney International 2 links

• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
• KDIGO Figure 13 Frequency of monitoring glomerular filtration rate (GFR) and albuminuria in people with chronic kidney disease (CKD)

National Kidney Foundation (NKF) 1 link

• CKDintercept

Nature Reviews Nephrology 1 link

• Measured and estimated glomerular filtration rate: current status and future directions

The New England Journal of Medicine 2 links

• New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
• Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease

National Kidney Foundation 4 links

• NKF Patient Journey: Chronic Kidney Disease (note- it may take a while to load the page)
• Estimated Glomerular Filtration Rate Fact Sheet (PDF)
• Estimated Glomerular Filtration Rate (eGFR)
• Try the New eGFR Calculator

UpToDate 1 link

• Patient education: Chronic kidney disease (Beyond the Basics)

National Kidney Foundation (NKF) 6 links

• Frequently Asked Questions about GFR Estimates
• Clinician Tools
• Laboratory Implementation of the NKF-ASN Task Force Reassessing the Inclusion of Race in Diagnosing Kidney Diseases
• eGFR Calculator
• Pediatric Chronic Kidney Disease Risk Calculator
• eGFR Calculator App

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1 link

• eGFR Calculators for Adults & Pediatrics

MDCalc 1 link

• CKD-EPI Equations for GFR

Kidney Failure Risk Equation 1 link

• The Kidney Failure Risk Equation

American Heart Association 1 link

• PREVENT Online Calculator

Kidney Disease Improving Global Outcomes (KDIGO) 2 links

• CKD Evaluation and Management – KDIGO
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Health Care Provider Resources 5 links

• 2024-2025 Respiratory Disease Season Outlook
• CDC Vaccine Schedules App for Healthcare Providers (2024)
• How to be a Vaccine Advocate
• Provider Toolkit: Preparing Patients for the Fall and Winter Virus Season for Respiratory Illnesses
• Statement on Immunizations from the ASN

RSV General Information 2 links

• Clinical Overview of RSV *
• RSV Vaccines

Adult Reccomendations 3 links

• Adult RSV ACIP Vaccine Recommendations
• Use of RSV Vaccines in Older Adults (2023)
• RSV Vaccination Recommendation for Adults (June 2024)

Infants and Young Children Reccomendations 2 links

• Use of Nirsevimab for the Prevention of RSV Among Infants and Young Children
• Vaccine Information Statement for RSV

• Racial and Ethnic Disparities in Use of and Outcomes with Home Dialysis in the United States
• Racial and Ethnic Disparities in Home Dialysis Use in the United States: Barriers and Solutions
• Payment System and Use of and Outcomes with Home Dialysis by Race and Ethnicity in the US

Promoting Confidence in COVID-19 Vaccinations for People with Kidney Diseases 6 links

• Vaccination rates are very low -- very few dialysis patients in the U.S. are up to date with COVID-19 vaccines.
• Rates for morbidity and mortality are high: (1) About half of all people with kidney disease had a hospital stay in the first 30 days of a COVID-19 diagnosis and (2) People with kidney diseases were twice as likely (compared to people without kidney diseases) to die within 90 days of a COVID-19 diagnosis.
• COVID-19 poses unique risks to people with kidney diseases: (1) People on dialysis can have weaker immune systems, making it harder to fight infections and (2) People with kidney diseases are at higher risk for more serious COVID-19 illness.
• COVID-19 had a huge impact on the kidney patient population: An impact so significant (so many patients died) that for the first time in the 50-year history of the Medicare End-Stage Renal Disease program, the total number of people on dialysis in the United States declined.
• Many years of research led to the COVID-19 vaccines. The science behind the COVID-19 vaccines was NOT rushed. In fact, these vaccines were developed after decades of scientific research.
• All of the traditional steps for testing, evaluation, and review were completed thoroughly. Vaccine developers did not cut corners – they cut government “red tape.” Because the pandemic was a true global emergency, there was a worldwide effort to remove usual bureaucratic hurdles.

The Benefits of Being Vaccinated Against COVID-19 2 links

• Prevents serious illness: COVID-19 vaccines available in the United States are safe and effective at protecting people from becoming seriously ill, being hospitalized, and dying.
• A safer way to build protection: Receiving a COVID-19 vaccine is a more lasting way to build protection than immunity after being sick with a COVID-19 infection. Vaccine-induced immunity offers protection against severe illness for at least six months. Infection-induced immunity diminishes after 90-days.

Promoting Vaccines: Know Facts and Bust Myths 3 links

• Myth: "I had a COVID shot last year." -- Fact: The current vaccine formulation is different from previous years and must be used to fight this year’s COVID-19 variant.
• Myth: "I will get sick from the COVID shot." -- Fact: Acknowledge some people may experience mild side effects (i.e., soreness or minor swelling) and give assurance that the vaccine does not cause illness and does not contain a “live virus.
• Myth: "I feel healthy, so I don't have to worry." -- Fact: As a dialysis patient or a staff member of a facility, you may be more vulnerable to infections, hospitalizations, complications, or spreading COVID-19.